Search Bar & Filters
Found 22 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating a new approach to selecting biologic treatments for adults with active Crohns Disease CD. This prospective, randomized study compares standard treatment selection to a method guided by epigenetic markers, aiming to assess which method better induces clinical remission and improves endoscopic response. The trial includes patients who are either new to biologic therapy or have used no more than one prior biologic treatment. The study is designed to measure efficacy, safety, and cost-effectiveness of this epigenome-guided approach. Participants are randomly assigned to one of two groups one receives biologic therapy based on epigenetic testing results using a specialized software called EpiPredict, which predicts response to two biologics, Vedolizumab VDZ or Ustekinumab UST. The other group receives biologic treatment chosen by their doctor following usual care guidelines without epigenetic information. Both groups receive their biologic treatments as labeled, with dosing adjustments allowed as needed by the treating physician. Throughout the 26-week treatment phase, participants undergo clinical assessments aligned with their biologic treatment schedules. Follow-up visits continue every six months up to two years, collecting data from medical records and online questionnaires. Researchers will measure clinical remission, endoscopic response, and cost-effectiveness among other outcomes to determine the value of using epigenetic markers in treatment selection for Crohns Disease.
Actively Recruiting
Researchers are evaluating the efficacy and safety of ifinatamab deruxtecan I-DXd in adults with unresectable advanced or metastatic esophageal squamous cell carcinoma ESCC who have experienced disease progression after treatment with platinum-based chemotherapy and immune checkpoint inhibitors. This phase 3 clinical trial compares I-DXd to the investigators choice of chemotherapy in this patient group to assess overall survival benefits. Participants are randomly assigned to receive either intravenous infusions of I-DXd at 12 mgkg every 21 days or investigator-selected chemotherapy drugs such as docetaxel, paclitaxel, or irinotecan hydrochloride. Treatment cycles repeat every three weeks, continuing until disease progression or other study endpoints. The study will measure overall survival, progression-free survival, objective response rate, duration of response, disease control rate, quality of life changes, safety events, and pharmacokinetic parameters for up to approximately 54 months. Throughout the study, participants will undergo regular assessments including imaging scans to measure tumor lesions, quality of life questionnaires, and safety monitoring for adverse events. Blood samples will be collected to analyze drug levels and immune responses. The studys main outcome is overall survival from randomization to death from any cause. Participants health and response to treatment will be followed closely during and after treatment for up to 54 months, with continued monitoring of safety and effectiveness measures.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of several investigational long-acting antibody treatments, both alone and in combination, for adults with moderately to severely active ulcerative colitis UC. This Phase 2 platform study involves multiple centers and aims to improve treatment options for this condition by comparing different therapies. The study consists of two parts. Part A was an open-label phase assessing safety and early effectiveness of three monotherapies, which completed enrollment in April 2026. Part B is currently enrolling and is a randomized, placebo-controlled phase testing three monotherapies and three combination therapies against placebo. Participants will receive intravenous induction and subcutaneous maintenance treatments, with different dosing regimens evaluated over time. Participants will be monitored through regular assessments including endoscopy and histology to measure disease activity and response. The main outcomes include clinical remission and histologic improvement after 12 weeks, with longer-term remission assessed up to 48 weeks. Safety and efficacy data will be collected throughout, with treatment duration and follow-up determined by study protocol. The total study completion is expected by March 2028.
Actively Recruiting
Researchers are studying the efficacy and safety of rilvegostomig combined with gemcitabine plus cisplatin compared to durvalumab combined with the same chemotherapy as first-line treatment for patients with advanced biliary tract cancer BTC. This Phase III, randomized, open-label study aims to evaluate these treatments in patients with unresectable locally advanced or metastatic BTC, including intra-hepatic or extra-hepatic cholangiocarcinoma and gallbladder carcinoma. Participants receive either rilvegostomig or durvalumab intravenously, both alongside gemcitabine and cisplatin chemotherapy. Durvalumab is given at 1500 mg IV every 3 weeks for up to 8 cycles, then every 4 weeks. Rilvegostomig is administered IV every 3 weeks. The chemotherapy regimen consists of gemcitabine 1000 mgm2 plus cisplatin 25 mgm2 on Day 1 and Day 8 of each 21-day cycle. Treatment continues according to the study protocol with close monitoring. During the study, participants undergo assessments including tumor measurements by CT or MRI using RECIST 1.1 criteria, evaluation of PD-L1 status, and performance status checks. Researchers also monitor overall survival and progression-free survival for up to approximately four years, as well as safety, tolerability, pharmacokinetics, and patient-reported symptoms and quality of life. Follow-up continues up to 12 weeks after disease progression for additional evaluations.
Actively Recruiting
This research focuses on adults with moderate-to-severe Crohns Disease CD, a chronic inflammatory condition of the digestive tract. It aims to evaluate how effective two approved drugs, upadacitinib and risankizumab, are as second-line treatments for CD in real-world clinical settings. Approximately 250 participants prescribed either drug by their physicians will be enrolled across 25 sites in Italy. Participants will receive either upadacitinib or risankizumab as part of their usual medical care, following local prescribing guidelines. The study includes a retrospective phase looking back up to 2 years before enrollment and a prospective phase where participants will be observed for up to 18 months after starting the medication. Both groups will be followed from their first dose throughout the study period. During this time, participants will not experience any additional study-related burden beyond their routine care. Researchers will review clinical records and monitor outcomes such as the percentage of participants achieving corticosteroid-free remission at 12 months. The study aims to gather real-world data on these treatments effectiveness and safety over time, with no extra visits or procedures required beyond standard practice.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of pumitamig combined with chemotherapy compared to bevacizumab combined with chemotherapy in adults with previously untreated, unresectable, or metastatic colorectal cancer. This phase 23 study aims to provide important information on treatment options for this type of advanced colorectal cancer. Participants will receive different combinations of study drugs, including pumitamig or bevacizumab, along with chemotherapy regimens such as FOLFOX, FOLFIRI, or CAPOX. The dosages are specified and given on designated days. The study uses a randomized, double-blind design to compare these treatments across multiple groups. During the study, participants will be closely monitored for tumor response, progression-free survival, and overall survival for up to five years. Evaluations include tumor measurements using RECIST criteria, safety assessments, and other clinical tests. This long-term follow-up helps researchers understand how well the treatments work and their effects over time.
Actively Recruiting
Hepatocellular carcinoma HCC is a common and deadly form of liver cancer that often develops in a liver damaged by scarring, making treatment difficult. This research is collecting and analyzing real-world patient data to evaluate the safety and effectiveness of new immunotherapy combinations like atezolizumab-bevacizumab and durvalumab-tremelimumab, and to find the best treatment sequences for advanced liver cancer. The study also aims to identify clinical and laboratory markers that predict how patients respond to these treatments to help personalize care. Participants in this observational study are patients with advanced liver cancer who are receiving frontline systemic therapy with atezolizumab-bevacizumab or other immunotherapies. The study collects data from everyday clinical practice without altering treatments. It focuses on new treatment combinations approved in recent years and aims to understand their real-world use and outcomes. The study monitors patients for up to three years from the start of their therapy. During the study, researchers review patient health, treatment responses, and side effects, tracking outcomes like toxicity, progression-free survival, overall survival, response rates, and eligibility for second-line treatments. Safety is monitored throughout the three-year period to provide comprehensive information on how these therapies work outside of clinical trials. This data will help guide future treatment decisions for liver cancer patients.
Actively Recruiting
Researchers are investigating changes in the lipidomic, immunological, and circulating microRNA profiles in adults with obesity and hepato-biliary diseases, such as hepatic steatosis or gallbladder inflammation. The study compares patients undergoing a dietary program with those receiving bariatric surgery, aiming to understand how these treatments affect metabolic and inflammatory changes related to obesity and liver pathology. This observational study considers the complex nature of obesity and its impact on patient health and quality of life. Participants will either follow a nutritional approach guided by a multidisciplinary team including doctors, dieticians, psychologists, and kinesiologists, or undergo bariatric surgery such as intragastric balloons, gastric bypass RYGB, or sleeve gastrectomy. The choice of intervention depends on the surgeons recommendation and the patients health status. Patients not suitable for surgery will be managed with dietary programs, emphasizing psychological support to address eating behavior disorders. During the study, researchers will assess lipidomic parameters, routine blood chemistry related to liver disease and fibrosis, and microRNA profiles at the start and after one year. Participants will be monitored through clinical visits, imaging like ultrasound and Fibroscan, and laboratory tests. The goal is to evaluate metabolic and inflammatory changes over time with each intervention, helping to inform future treatment strategies for obesity and associated liver conditions.
Actively Recruiting
Researchers are evaluating whether continuing cetuximab treatment beyond first-line progression can improve outcomes in adults with metastatic colorectal cancer who have tumors that are RAS and BRAF wild-type. This Phase 3 clinical trial aims to compare chemotherapy combined with cetuximab versus chemotherapy combined with bevacizumab, focusing on tumor response, progression-free survival, overall survival, and safety. The study builds on prior trials suggesting potential benefits of cetuximab continuation in this patient group. Participants will be randomly assigned to receive either FOLFOX or FOLFIRI chemotherapy combined with cetuximab experimental group or bevacizumab control group. Treatments are given every two weeks, with cetuximab administered as a 120-minute intravenous infusion at 500 mgm and bevacizumab at 5 mgkg. Therapy continues until disease progression, unacceptable side effects, or patient withdrawal. Tumor response will be assessed by independent review using RECIST criteria. During the study, patients undergo regular CT or MRI scans, laboratory tests, and clinical evaluations. Biological samples such as tumor tissue, blood, and stool are collected for research on resistance mechanisms and the gut microbiome. The primary measure is the overall response rate assessed up to 48 months, with secondary outcomes including overall survival, progression-free survival, and safety monitored throughout treatment and up to 30 days after the last dose. Participation lasts through treatment and follow-up periods up to several years.
Actively Recruiting
Healthy Volunteer
Researchers are investigating how two different exercise programs combined with a Mediterranean diet compare to the diet alone in reducing inflammation among adults aged 18 to 65 years who have obesity and Non-Alcoholic Fatty Liver Disease NAFLD. The study aims to measure various inflammatory markers and understand the impact on body composition, physical fitness, gut microbiota, quality of life, and fatty acid profiles after a 4-month intervention. Participants will be randomly assigned to one of three groups one group will follow the Mediterranean diet and engage in moderate-intensity aerobic exercise outdoor walking for 180 minutes per week another will follow the diet combined with high-intensity interval training HIIT in a gym setting for 150 minutes per week and the third group will follow the Mediterranean diet alone. All participants will receive guidance from specialized staff on both diet and exercise. During the study, participants will undergo assessments at the start, midpoint, and end of the 4 months, including measurements of systemic inflammation, body composition, gut microbiota analysis, quality of life questionnaires, fatty acid profiles, and evaluations related to sarcopenia risk and intestinal health. The primary outcome focuses on changes in systemic inflammatory status between baseline and day 120. The study will include monitoring to ensure adherence and safety throughout the participation period.
1-10 of 22
1